Immunotherapy for B-cell lymphoma: current status and prospective advances.

Frontiers in Immunology
N Hollander

Abstract

Therapy for non-Hodgkin's lymphoma has progressed significantly over the last decades. However, the majority of patients remain incurable, and novel therapies are needed. Because immunotherapy ideally offers target selectivity, an ever increasing number of immunotherapies, both passive and active, are undergoing development. The champion of passive immunotherapy to date is the anti-CD20 monoclonal antibody rituximab that revolutionized the standard of care for lymphoma. The great success of rituximab catalyzed the development of new passive immunotherapy strategies that are currently undergoing clinical evaluation. These include improvement of rituximab efficacy, newer generation anti-CD20 antibodies, drug-conjugated and radio labeled anti-CD20 antibodies, monoclonal antibodies targeting non-CD20 lymphoma antigens, and bispecific antibodies. Active immunotherapy aims at inducing long-lasting antitumor immunity, thereby limiting the likelihood of relapse. Current clinical studies of active immunotherapy for lymphoma consist largely of vaccination and immune checkpoint blockade. A variety of protein- and cell-based vaccines are being tested in ongoing clinical studies. Recently completed phase III clinical trials of an idiotype p...Continue Reading

Citations

Sep 6, 2014·Expert Opinion on Biological Therapy·Tim IllidgeJamie Honeychurch
Feb 15, 2013·Human Vaccines & Immunotherapeutics·Elena MuraroRiccardo Dolcetti
Jan 30, 2015·Cancer Immunology Research·Amani MakkoukGeorge J Weiner
Dec 20, 2014·Cancer Research·Amani Makkouk, George J Weiner
Dec 5, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laura MarconatoLuca Aresu

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotide
antisense oligonucleotides
PCR

Clinical Trials Mentioned

NCT00494780
NCT00546793
NCT00354926
NCT01287741
NCT01059630
NCT00006721
NCT00848926
NCT00670592
NCT01275209
NCT01030900

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Joshua BrodyRonald Levy
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Peter MartinJohn P Leonard
© 2021 Meta ULC. All rights reserved